After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

SAGE has experienced a substantial decline in its stock price, down about 80% in the past year, partly due to setbacks in its drug pipeline, including the discontinuation of zuranolone for major ...

Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years, as its ...

Sage discontinues Zulresso, drops pair of pipeline prospects as it creeps toward 2026 cash cliff Several factors have played into the sharp decline, notably including the failure of zuranolone to ...

That was the challenge for Sage Pay, who had a pipeline gap for their payment gateway software and only held 6% market share among retail and hospitality SMEs. Even if their payment gateway wasn’t ...

January 12, 2025--(BUSINESS WIRE)--Sage Therapeutics ... the Company’s recalibrated R&D approach and its prioritized pipeline focused on neurodevelopmental disorders and neuropsychiatry.

A major setback for Sage occurred in late 2024 when its key pipeline drug, dalzanemdor, failed to show clinical benefit in the DIMENSION study for Huntington's Disease. This failure led to the ...